GlassScriptPhysician profile
Faiza Husain
NPI 1952831539
$584.44
in general payments reported to CMS, 2019-2025
10 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.69 · 2023: $141 · 2024: $48.92 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $189.97 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $71.22 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $62.01 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $52.85 | 2023-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $46.74 | 2025 | |
| Ardelyx, INC. | $45.64 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $38.88 | 2025 | Velphoro |
| Alexion Pharmaceuticals, INC. | $35.07 | 2022-2023 | Ultomiris |
| Csl Behring | $26.70 | 2024 | Haegarda |
| Vifor Pharma, INC. | $15.36 | 2023 | Veltassa, Korsuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiza Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.